Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966002 · ClinicalTrials.gov registry record · Phase 4
Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients
A Phase 4 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT02966002 is a Phase 4 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 9 participants.
The verdict
NCT02966002, a Phase 4 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
Patients who have undergone the Fontan procedure (a congenital heart surgery) may develop complications many years after their operation. Studies have shown that some of these patients develop an ongoing inflammatory state, which may be the cause of these late complications. Aspirin is a common over the counter anti-inflammatory medication used for many other chronic diseases. This study may help determine if aspirin therapy can limit the inflammation seen in Fontan patients and prevent these late complications.
Interventions
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-05-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02966002
The ClinicalTrials.gov registry entry for NCT02966002 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.
NCT02966002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02966002 about?
NCT02966002 is a clinical study titled "Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients". Patients who have undergone the Fontan procedure (a congenital heart surgery) may develop complications many years after their operation. Studies have shown that some of these patients develop an ongoing inflammatory state, which may be the cause of these late complications. Aspirin is a common over...
What is the current status of trial NCT02966002?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2016-04. Estimated completion is 2017-05-25.
What interventions are being tested in trial NCT02966002?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT02966002?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.